PAVmed (NASDAQ:PAVM) Upgraded by ValuEngine to “Buy”

ValuEngine upgraded shares of PAVmed (NASDAQ:PAVM) from a hold rating to a buy rating in a report released on Thursday morning, ValuEngine reports.

Separately, Maxim Group reaffirmed a buy rating on shares of PAVmed in a research report on Thursday, May 23rd.

Shares of NASDAQ:PAVM traded down $0.01 during midday trading on Thursday, reaching $1.03. The company’s stock had a trading volume of 93,800 shares, compared to its average volume of 140,572. The business has a 50 day moving average of $1.10. PAVmed has a 12-month low of $0.86 and a 12-month high of $1.54.

PAVmed (NASDAQ:PAVM) last released its earnings results on Tuesday, May 21st. The company reported ($0.09) earnings per share for the quarter.

In other PAVmed news, CEO Lishan Aklog bought 30,000 shares of PAVmed stock in a transaction dated Thursday, May 23rd. The shares were purchased at an average cost of $1.10 per share, with a total value of $33,000.00. Following the transaction, the chief executive officer now directly owns 848,413 shares of the company’s stock, valued at $933,254.30. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 34.40% of the stock is owned by corporate insiders.

An institutional investor recently raised its position in PAVmed stock. CWM LLC increased its position in PAVmed Inc (NASDAQ:PAVM) by 206.7% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 46,000 shares of the company’s stock after purchasing an additional 31,000 shares during the period. CWM LLC owned approximately 0.15% of PAVmed worth $52,000 at the end of the most recent reporting period. 1.82% of the stock is currently owned by hedge funds and other institutional investors.

PAVmed Company Profile

PAVmed Inc operates as a medical device company in the United States. The company's lead product pipeline includes CarpX, a percutaneous device to treat carpal tunnel syndrome; EsoCheck, an non-invasive cell collection device and DNA biomarkers to detect esophageal cancer precursor; PortIO, an implantable intraosseous vascular access device; and DisappEAR, an antimicrobial resorbable ear tube.

Read More: How is the LIBOR rate calculated?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for PAVmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed and related companies with MarketBeat.com's FREE daily email newsletter.